CDK4 and breast cancer: The CDK4/6i used in the clinical practice are palbociclib, approved by the US Food and Drug Administration (FDA) in 2015 for the treatment of postmenopausal HR+/HER2− advanced breast cancer (ABC) in combination with hormone treatment (letrozole or fulvestrant); ribociclib; and abemaciclib.